Loading
Raynaud Disease · Journal article
International Journal of Hyperthermia · April 13, 2026
Encouraging direction, but not yet definitive.
This randomized controlled trial evaluated whether adding water-filtered infrared-A (wIRA) irradiation to standard iloprost and CO2 hand bath therapy improves outcomes in systemic sclerosis patients with severe Raynaud's phenomenon. The addition of wIRA produced a statistically significant but clinically modest reduction in pain and RP duration, with no significant effects on other secondary outcomes or biomarkers.
Randomized, controlled trial. Patients with systemic sclerosis and severe Raynaud's phenomenon. Intervention: Water-filtered infrared-A (wIRA) irradiation 2 × 30 min/day for 8 days plus iloprost and CO2 hand baths. Compared with: Iloprost plus CO2 hand baths alone. n = 38.
Pain decreased from 70.4 ± 27.8 to 56.7 ± 21.4 mm with wIRA versus 73.9 ± 27.5 to 65.3 ± 26.8 mm in controls Mean difference in pain was -14.7 mm, 95% CI [-28.8;-0.7], p = 0.041 in favor of wIRA RP duration improved more in the wIRA group at day 23: β = -3.8, 95% CI [-7.4;-0.2], p = 0.041
No adverse events occurred in either group
The addition of water-filtered infrared-A therapy to standard iloprost and CO2 hand baths resulted in a statistically significant but modest pain reduction (approximately 15 mm on VAS) and improved RP duration. Clinicians should weigh the logistical demands of twice-daily 30-minute wIRA sessions against the modest short-term benefit, pending confirmation in larger trials.
Small randomized controlled trial showing statistically significant but modest pain reduction with adjunctive water-filtered infrared-A therapy in systemic sclerosis; requires larger validation.
As stated by the source record.
Quoted from the source exactly as published.
The addition of water-filtered infrared-A therapy to standard iloprost and CO2 hand baths resulted in a statistically significant but modest pain reduction (approximately 15 mm on VAS) and improved RP duration. Clinicians should weigh the logistical demands of twice-daily 30-minute wIRA sessions against the modest short-term benefit, pending confirmation in larger trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Almost all patients with systemic sclerosis (SSc) experience Raynaud's phenomenon (RP) with risk of digital ulcers (DU). In severe RP, intravenous iloprost is standard, yet additive hyperthermic therapy may enhance vasodilation and microcirculation. However, whether more intensive or alternative hyperthermic modalities offer benefits beyond commonly used CO2 hand baths remains unclear.Methods. In this randomized, controlled trial, all patients received a baseline therapy of iloprost plus CO2 hand baths. The intervention group (IG) received additional water-filtered infrared-A (wIRA; 2 × 30 min/day, 8 days), while the control group (CG) received baseline therapy alone. The primary endpoint was the difference in RP-associated pain (VAS 0-100 mm) after treatment. Secondary outcomes included changes in RP duration, frequency, and intensity, Health Assessment Questionnaire (HAQ), serum interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF).Results. Of 46 randomized patients, 38 (IG = 19, CG = 19) completed the study. Pain decreased from 70.4 ± 27.8 to 56.7 ± 21.4 mm with wIRA and from 73.9 ± 27.5 to 65.3 ± 26.8 mm in controls. Multivariable ANCOVA showed a mean difference of -14.7, 95% CI [-28.8;-0.7], p = 0.041 in favor of wIRA. RP duration improved more in the wIRA group (day 23: β = -3.8, 95% CI [-7.4;-0.2], p = 0.041), while RP frequency, intensity, HAQ, IL-6, and VEGF showed no significant differences (all p > 0.05). No adverse events occurred.Conclusions. Adjunctive wIRA during iloprost therapy was safe and yielded modest, short-term improvements in pain and RP duration. These exploratory effects warrant confirmation in larger controlled trials.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.